RESUMO
BACKGROUND: Hemochromatosis is a genetic condition of iron overload caused by deficiency of hepcidin. In a previous stage of this study, patients with suspected hemochromatosis had their quality of life (QL) measured. We observed that QL scores differed among genotypic groups of patients. In this reported final phase of the study, the aims were to compare QL scores after a treatment period of approximately 3 years and to analyze a possible association of the serum ferritin values with QL scores. METHODS: Sixty-five patients were enrolled in this final phase and divided into group 1 (patients that showed primary iron overload and homozygous genotype for the HFE p.Cys282Tyr mutation) and group 2 (other kinds of genotypes). Short Form 36 (SF-36) was performed and consisted of eight domains with a physical and also a mental component. RESULTS: Both groups had a significant decrease in serum ferritin concentrations: group 1 had a variation from 1844 ± 1313 ng/mL to 281 ± 294 ng/mL, and group 2 had a variation from 1216 ± 631 ng/mL to 236 ± 174 ng/mL. Group 1 had a smaller mean value for these six SF-36 domains compared with group 2, indicating a worse QL. CONCLUSIONS: In this final stage, six domains demonstrated a difference among genotypic groups (role emotional and mental health, adding to the four of the initial phase), reassuring the impact of the identified genotype on the QL of hemochromatosis patients. Furthermore, despite that both patient groups demonstrated similar and significant decreases in serum ferritin values, no association was found between the decrease in this biological parameter and the SF-36 domains.
Assuntos
Ferritinas/sangue , Proteína da Hemocromatose/genética , Hemocromatose/diagnóstico , Hemocromatose/genética , Proteínas de Membrana/genética , Mutação , Qualidade de Vida , Predisposição Genética para Doença , Genótipo , Hemocromatose/sangue , HumanosRESUMO
INTRODUCTION: Early diagnosis and identification of potential critical cases for timely treatment are crucial for COVID-19 patients. The aim of this study was to analyze the diagnostic and prognostic implications of WBC and cell population data (CPD) abnormalities related to COVID-19 at disease onset. METHODS: Baseline WBC counts and CPD data were analyzed in one hundred COVID-19 patients presenting to emergency department and subsequently discharged (n=49), admitted (n=51) or deceased (n=22), and in 47 healthy subjects. RESULTS: Lymphopenia and eosinopenia were observed in all COVID-19 patients, with more intensity in the admitted and deceased groups, that also presented increased WBC and neutrophil counts. On CPD analysis, COVID-19 was associated with increased volume of neutrophils, lymphocytes, and monocytes, whereas conductivity was decreased for neutrophils and increased for lymphocytes. The ROC curve analysis showed good performance for lymphocyte counts in predicting COVID-19 diagnosis (AUC=0.858), for neutrophil counts in predicting admission for COVID-19 (AUC=0.744) and for monocytes volume in predicting COVID-19 diagnosis (AUC=0.837). CONCLUSION: WBC counts and CPD parameters at disease onset in COVID-19 patients can improve diagnostic characterization and aid in the discrimination between severe and nonsevere presentations.
Assuntos
COVID-19/sangue , Contagem de Leucócitos , Pandemias , SARS-CoV-2 , Adulto , Área Sob a Curva , COVID-19/diagnóstico , COVID-19/mortalidade , Teste para COVID-19 , Condutividade Elétrica , Citometria de Fluxo , Humanos , Pacientes Internados , Pacientes Ambulatoriais , Prognóstico , Curva ROC , Estudos Retrospectivos , Risco , Sensibilidade e Especificidade , Análise de SobrevidaRESUMO
BACKGROUND: Five main genes are associated with hemochromatosis; however, current studies show that, in addition to these genes, others may be associated with primary iron overload (IO). One of these is the bone morphogenetic protein 6 (BMP6), which encodes a protein that modulates hepcidin synthesis and, consequently, iron homeostasis. AIM: To identify BMP6 gene pathogenic variants in patients with IO and non-homozygous genotype for the HFE p.Cys282Tyr mutation. MATERIALS AND METHODS: Fifty-three patients with primary IO and non-homozygous genotype for the HFE p.Cys282Tyr were selected. Subsequent bidirectional DNA sequencing of BMP6 exons was performed. RESULTS: Two novel variants were found. One at homozygous state p.Gln158Ter (c.472C>T) was pathogenic, the other one at heterozygous state p.Val394Met (c.1180G>A) was of uncertain significance (VUS); the third variant at heterozygous state p.Arg257His (c.770G>A) has already been described and associated with IO. No BMP6 pathogenic variants that would explain iron overload phenotypes were detected in 94% of the studied patients. CONCLUSION: Identification of the BMP6 pathogenic variants in Brazilian patients with primary IO might contribute to the genetic understanding of this phenotype.
Assuntos
Proteína Morfogenética Óssea 6/genética , Sobrecarga de Ferro/genética , Mutação Puntual , Adulto , Feminino , Heterozigoto , Homozigoto , Humanos , Masculino , Pessoa de Meia-IdadeAssuntos
Humanos , Masculino , Pré-Escolar , Talassemia beta , Anemia Hemolítica , Anemia HipocrômicaRESUMO
BACKGROUND: Hereditary hemochromatosis (HH) encompasses a group of autosomal recessive disorders mainly characterized by enhanced intestinal absorption of iron and its accumulation in parenchymal organs. HH diagnosis is based on iron biochemical and magnetic resonance imaging (MRI) assessment, and genetic testing. Questionnaires, such as SF-36 (short form health survey), have been increasingly used to assess the impact of diseases on the patient's quality of life (QL). In addition, different genotypes are identified as results of genetic tests in patients with suspected primary iron overload. In the present study, our aim was to evaluate whether domains of QL are different according to genotypic groups in patients suspected of HH. METHODS: Seventy-nine patients with primary iron overload were included and two genotypic groups were formed (group 1: homozygous genotype for the HFE p.Cys282Tyr mutation; group 2: other genotypes). RESULTS: Group 1 had higher means of plasma transferrin saturation (86 ± 19%) and serum ferritin (1669 ± 1209 ng/mL) compared to group 2 (71 ± 12%, 1252 ± 750 ng/mL, respectively; p = 0.001). Four domains were significantly different among groups 1 and 2: physical functioning (p = 0.03), bodily pain (p = 0.03), vitality (p = 0.02) and social functioning (p = 0.01). CONCLUSIONS: Our main finding was that patients with p.Cys282Tyr homozygosity had a worse QL scenario assessed by SF-36, compared with patients with iron overload without the same genotype. Being aware of this relationship between genotypes and QL might be helpful in the overall management of patients suspected of hereditary hemochromatosis.
Assuntos
Predisposição Genética para Doença , Hemocromatose/diagnóstico , Hemocromatose/genética , Qualidade de Vida , Adulto , Feminino , Ferritinas/sangue , Testes Genéticos , Genótipo , Homozigoto , Humanos , Ferro/sangue , Sobrecarga de Ferro/sangue , Sobrecarga de Ferro/diagnóstico , Sobrecarga de Ferro/genética , Masculino , Pessoa de Meia-Idade , Mutação , Fatores Socioeconômicos , Inquéritos e Questionários , Transferrina/metabolismoRESUMO
ABSTRACT Anemia is a frequent complication in cancer patients, both at diagnosis and during treatment, with a multifactorial etiology in most cases. Iron deficiency is among the most common causes of anemia in this setting and can develop in nearly half of patients with solid tumors and hematologic malignancies. Surprisingly, this fact is usually neglected by the attending physician in a way that proper and prompt investigation of the iron status is either not performed or postponed. In cancer patients, functional iron deficiency is the predominant mechanism, in which iron availability is reduced due to disease or the therapy-related inflammatory process. Hence, serum ferritin is not reliable in detecting iron deficiency in this setting, whereas transferrin saturation seems more appropriate for this purpose. Besides, lack of bioavailable iron can be further worsened by the use of erythropoiesis stimulating agents that increase iron utilization in the bone marrow. Iron deficiency can cause anemia or worsen pre-existing anemia, leading to a decline in performance status and adherence to treatment, with possible implications in clinical outcome. Due to its frequency and importance, treatment of this condition is already recommended in many specialty guidelines and should be performed preferably with intravenous iron. The evidences regarding the efficacy of this treatment are solid, with response gain when combined with erythropoiesis stimulating agents and significant increments in hemoglobin as monotherapy. Among intravenous iron formulations, slow release preparations present more favorable pharmacological characteristics and efficacy in cancer patients.
Assuntos
Anemia Ferropriva/terapia , Injeções Intravenosas/estatística & dados numéricos , /terapia , Neoplasias/complicaçõesRESUMO
Anemia is a frequent complication in cancer patients, both at diagnosis and during treatment, with a multifactorial etiology in most cases. Iron deficiency is among the most common causes of anemia in this setting and can develop in nearly half of patients with solid tumors and hematologic malignancies. Surprisingly, this fact is usually neglected by the attending physician in a way that proper and prompt investigation of the iron status is either not performed or postponed. In cancer patients, functional iron deficiency is the predominant mechanism, in which iron availability is reduced due to disease or the therapy-related inflammatory process. Hence, serum ferritin is not reliable in detecting iron deficiency in this setting, whereas transferrin saturation seems more appropriate for this purpose. Besides, lack of bioavailable iron can be further worsened by the use of erythropoiesis stimulating agents that increase iron utilization in the bone marrow. Iron deficiency can cause anemia or worsen pre-existing anemia, leading to a decline in performance status and adherence to treatment, with possible implications in clinical outcome. Due to its frequency and importance, treatment of this condition is already recommended in many specialty guidelines and should be performed preferably with intravenous iron. The evidences regarding the efficacy of this treatment are solid, with response gain when combined with erythropoiesis stimulating agents and significant increments in hemoglobin as monotherapy. Among intravenous iron formulations, slow release preparations present more favorable pharmacological characteristics and efficacy in cancer patients.
RESUMO
Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). There is a concern that labile plasma iron (LPI), the redox-active form of iron, can be involved in the occurrence of toxicity and other complications commonly observed in the early post-HSCT period. In order to better understand the LPI kinetics and its determinants and implications, we undertook sequential LPI determinations before and after conditioning until engraftment in 25 auto-HSCT patients. Increased LPI was present in only 5 patients before starting conditioning. Shortly after conditioning, LPI levels were increased in 23 patients, with peak at day 0, returning to normal range upon engraftment in 21 patients. Overall, LPI levels correlated weakly with serum ferritin and more strongly with transferrin saturation; however, both parameters were apparently not applicable as surrogate markers for increased LPI. Although this was a small cohort, logistic regression suggested that baseline LPI levels could predict occurrence of grade III or IV toxicity. In conclusion, LPI kinetics is influenced by aplasia following conditioning and engraftment. Measuring LPI before starting conditioning can offer an opportunity to predict toxicity and, perhaps, the need for chelation therapy.
Assuntos
Sobrevivência de Enxerto , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Sobrecarga de Ferro/etiologia , Ferro/sangue , Condicionamento Pré-Transplante/efeitos adversos , Adulto , Idoso , Antioxidantes/química , Ácido Ascórbico/química , Estudos de Coortes , Deferiprona , Feminino , Corantes Fluorescentes/química , Seguimentos , Humanos , Ferro/química , Quelantes de Ferro/química , Sobrecarga de Ferro/sangue , Sobrecarga de Ferro/fisiopatologia , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Piridonas/química , Rodaminas/química , Índice de Gravidade de Doença , Adulto JovemRESUMO
Alterações no perfil de ferro já foram descritas em pacientes submetidos à quimioterapia de altas doses com transplante de células precursoras hematopoiéticas (TCPH), e uma possível relação entre o metabolismo do ferro e a reconstituição hematopoiética pós-transplante, embora proposta, ainda carece de confirmação. Com o objetivo de avaliar as alterações do perfil de ferro e a sua correlação com a recuperação hematológica pós-TCPH, foram determinados a saturação da transferrina (ST), ferro e ferritina séricos em 21 pacientes submetidos a TCPH, antes do transplante e prospectivamente no dia 0, no dia +14 e no dia +180. Após a quimioterapia de altas doses, todos os parâmetros analisados se elevaram acentuadamente no dia 0 e permaneceram ainda alterados no dia +14; após 180 dias, observou-se uma tendência de retorno para valores próximos aos obtidos antes do transplante. No dia +14, os valores de ST apresentaram forte correlação inversa com a contagem absoluta de leucócitos (p<0,0001) e de reticulócitos (p<0,05), e uma correlação direta com o tempo de enxertia (p<0,0001). Nossos resultados demonstram que o perfil de ferro se altera de forma aguda e significativa após a quimioterapia de altas doses com TCPH e que tais alterações estão aparentemente correlacionadas com a atividade hematopoiética após o transplante.
Assuntos
Transplante de Células-Tronco Hematopoéticas , Transferrina , Transplante de Células , Distúrbios do Metabolismo do Ferro , Eritropoese , Doenças Hematológicas , FerroRESUMO
Oxygen-derived free radical damage is associated with the molecular toxicity of hemoglobin. Especially in thalassemia syndromes, this toxicity has a relationship with "free" alpha globin concentrations. This study of beta thalassemia trait blood samples from 39 individuals shows that the evaluation of methemoglobin is a sensitive method of indicating molecular toxicity and the superoxide dismutase concentration revealing the intensity of oxidative stress of this process.